u/OldRate5407

Today, PSTV signed an insurance contract with Blue Shield of California, increasing their total covered lives from 75 million to 81 million.

However, the implications of this extend far beyond a simple addition of 6 million lives.

.

.

1) California is the most populous state in the US, with 39 million residents.

This population is covered by Medicare and commercial insurers. The commercial landscape includes:

Kaiser Permanente: ~9 million (Largest in California)

Anthem Blue Cross of California: ~8 million

Blue Shield of California: ~6 million

Others (Health Net, Molina, Aetna, etc.): The remainder

When a specific test like CNSide is covered by only one insurer in a state, complaints from patients and physicians under other plans create strong pressure to expand coverage.

.

.

2) A crucial point is that Blue Shield of California is a licensee under the BCBS umbrella.

Its competitor, Anthem Blue Cross of California, is also a BCBS licensee and a subsidiary of Elevance Health (formerly Anthem), the second-largest insurer in the US.

Elevance Health holds BCBS licenses in 14 states and covers over 46 million members. Elevance Health operates a unified medical policy at the corporate level.

This means that the pressure generated by Blue Shield of California will likely impact not just Anthem Blue Cross of California (8 million lives), but potentially scale up to the entire Elevance Health network (46 million lives).

.

.

3) Most importantly, this marks the beginning of the BCBS domino effect.

Highmark, which signed a contract recently (April 1, 2026), is the 5th largest BCBS licensee.

To briefly explain the BCBS structure: BCBSA (Blue Cross Blue Shield Association) is an umbrella organization with 36 independent licensee companies.

These 36 independent BCBS plans cover 106 million Americans.

Each makes its own local coverage decisions, but they utilize evaluations from Evidence Street as part of their decision-making process.

The Highmark contract had the potential to trigger a domino effect among other BCBS licensees.

Indeed, less than a month later, Blue Shield of California has been added.

This significantly increases the probability that the momentum will carry over to Elevance Health, the second-largest insurer overall. (as their corporate-level policy is applied uniformly across subsidiaries in 14 states, rather than individually by state).

Furthermore, it is highly likely to accelerate the domino effect leading to additional contracts with BCBS-affiliated insurers.

.

.

4) PSTV's goal is to secure 150 million covered lives by the end of this year.

Fundamentally, the evidence base for CNSide has been robust, and their pace of securing coverage is remarkably fast for the industry.

(1) 9 Peer-reviewed publications: Three times the minimum requirement (3 publications) set by the AMA when applying for a Category I CPT code.

(2) FORESEE clinical trial: Prospective clinical trial data.

(3) 11,000 cumulative uses across 120 cancer centers: Proof of real-world evidence and clinical adoption.

(4) Sensitivity 92%, Specificity 95%: Exceptionally high diagnostic performance.

(5) Influenced treatment decisions in 90% of cases: Direct evidence of clinical utility.

(6) 40% cost reduction (ISPOR): The cost-effectiveness data that payers most want to see.

.

.

With an evidence base of this caliber, the fact that major insurers like UNH and Humana initiated coverage within 6 weeks of each other served as market validation of the evidence quality.

Furthermore, there were catalysts in April designed to accelerate payer negotiations:

(26.04.07) Approval of PLA code 0640U: Secured a standard billing pathway. In future negotiations, the weakness of being a "test without a code" is eliminated.

(26.04.13)Hiring of Randy Goodman: A 20-year veteran in payer strategy is now leading negotiations in-house, replacing their previous reliance on external consultants.

(26.04.20) Hiring of Eric Daniels as CMO: Strengthening clinical development.

(26.03.19) ISPOR Health Economics Analysis: Showcased ~40% cost-savings data, representing the most persuasive leverage for payers.

.

Now, we are beginning to see concrete results. This is why the Blue Shield of California contract means much more than just 6 million additional lives.

.

.

The stock climbed 170% from its bottom in two weeks, and the recent pullback has been excessive.

The company remains in a state of extreme undervaluation.

Business execution is proceeding exceptionally well.

.

Around September of last year, when the stock was trading at $0.50 (split-adjusted $12.50), a contract with UnitedHealthcare was announced, and the stock more than doubled.

Today, both the diagnostic and therapeutic divisions have made significantly more progress than they had back then.

Within this year, numerous milestones are expected, including additional payer contracts, Medicare approval, clinical results for LM/GBM therapeutics, and a meeting with the FDA for the pivotal trial.

.

.

If you extend your investment horizon just slightly to the end of this year, the upside potential for this company is highly compelling.

GLTA

https://www.reddit.com/r/pennystocks/comments/1sew1c0/pstv_a_realistic_10bagger_from_current_levels/

Part 1: Overall reasons for the upside (Diagnostics + Therapeutics + Cash)

https://www.reddit.com/r/pennystocks/comments/1sgrkee/pstv_genuinely_has_ample_potential_for_a_10x/

Part 2: Fact-checking the Diagnostic Division (CNSide)

https://www.reddit.com/r/pennystocks/comments/1skda4f/pstv_still_holds_more_than_5x_upside_potential/

Part 3: Details of the Therapeutics Division (REYOBIQ)

.

.

When I first wrote about PSTV here 20 days ago, I received significant criticism, but the stock subsequently surged by over 170% in the short term.

At the time, I perceived an asymmetric situation with extremely low risk and massive upside potential, which is why I posted several analytical reviews of PSTV.

Following the explosive rally, the stock experienced an excessive pullback, and today, the diagnostic division announced an additional commercial payer contract.

The company remains in a deeply undervalued territory relative to its intrinsic value. Because this new insurance contract carries much stronger momentum than the public realizes, I am posting another analysis of PSTV.

As a shareholder, I acknowledge that I may have a positive bias, and there is a promotional aspect to my post. However, I have absolutely no intention of harming others by spreading false hype during unfavorable times.

I believe that if you review my posts and conduct further objective analysis on PSTV, you will find a solid opportunity.

----------------------------------------

Today, PSTV signed an insurance contract with Blue Shield of California, increasing their total covered lives from 75 million to 81 million.

However, the implications of this extend far beyond a simple addition of 6 million lives.

.

.

1) California is the most populous state in the US, with 39 million residents.

This population is covered by Medicare and commercial insurers. The commercial landscape includes:

Kaiser Permanente: ~9 million (Largest in California)

Anthem Blue Cross of California: ~8 million

Blue Shield of California: ~6 million

Others (Health Net, Molina, Aetna, etc.): The remainder

When a specific test like CNSide is covered by only one insurer in a state, complaints from patients and physicians under other plans create strong pressure to expand coverage.

.

.

2) A crucial point is that Blue Shield of California is a licensee under the BCBS umbrella.

Its competitor, Anthem Blue Cross of California, is also a BCBS licensee and a subsidiary of Elevance Health (formerly Anthem), the second-largest insurer in the US.

Elevance Health holds BCBS licenses in 14 states and covers over 46 million members. Elevance Health operates a unified medical policy at the corporate level.

This means that the pressure generated by Blue Shield of California will likely impact not just Anthem Blue Cross of California (8 million lives), but potentially scale up to the entire Elevance Health network (46 million lives).

.

.

3) Most importantly, this marks the beginning of the BCBS domino effect.

Highmark, which signed a contract recently (April 1, 2026), is the 5th largest BCBS licensee.

To briefly explain the BCBS structure: BCBSA (Blue Cross Blue Shield Association) is an umbrella organization with 36 independent licensee companies.

These 36 independent BCBS plans cover 106 million Americans.

Each makes its own local coverage decisions, but they utilize evaluations from Evidence Street as part of their decision-making process.

The Highmark contract had the potential to trigger a domino effect among other BCBS licensees.

Indeed, less than a month later, Blue Shield of California has been added.

This significantly increases the probability that the momentum will carry over to Elevance Health, the second-largest insurer overall. (as their corporate-level policy is applied uniformly across subsidiaries in 14 states, rather than individually by state).

Furthermore, it is highly likely to accelerate the domino effect leading to additional contracts with BCBS-affiliated insurers.

.

.

4) PSTV's goal is to secure 150 million covered lives by the end of this year.

Fundamentally, the evidence base for CNSide has been robust, and their pace of securing coverage is remarkably fast for the industry.

(1) 9 Peer-reviewed publications: Three times the minimum requirement (3 publications) set by the AMA when applying for a Category I CPT code.

(2) FORESEE clinical trial: Prospective clinical trial data.

(3) 11,000 cumulative uses across 120 cancer centers: Proof of real-world evidence and clinical adoption.

(4) Sensitivity 92%, Specificity 95%: Exceptionally high diagnostic performance.

(5) Influenced treatment decisions in 90% of cases: Direct evidence of clinical utility.

(6) 40% cost reduction (ISPOR): The cost-effectiveness data that payers most want to see.

.

.

With an evidence base of this caliber, the fact that major insurers like UNH and Humana initiated coverage within 6 weeks of each other served as market validation of the evidence quality.

Furthermore, there were catalysts in April designed to accelerate payer negotiations:

(26.04.07) Approval of PLA code 0640U: Secured a standard billing pathway. In future negotiations, the weakness of being a "test without a code" is eliminated.

(26.04.13)Hiring of Randy Goodman: A 20-year veteran in payer strategy is now leading negotiations in-house, replacing their previous reliance on external consultants.

(26.04.20) Hiring of Eric Daniels as CMO: Strengthening clinical development.

(26.03.19) ISPOR Health Economics Analysis: Showcased ~40% cost-savings data, representing the most persuasive leverage for payers.

.

Now, we are beginning to see concrete results. This is why the Blue Shield of California contract means much more than just 6 million additional lives.

.

.

The stock climbed 170% from its bottom in two weeks, and the recent pullback has been excessive.

The company remains in a state of extreme undervaluation.

Business execution is proceeding exceptionally well.

.

Around September of last year, when the stock was trading at $0.50 (split-adjusted $12.50), a contract with UnitedHealthcare was announced, and the stock more than doubled.

Today, both the diagnostic and therapeutic divisions have made significantly more progress than they had back then.

Within this year, numerous milestones are expected, including additional payer contracts, Medicare approval, clinical results for LM/GBM therapeutics, and a meeting with the FDA for the pivotal trial.

.

.

If you extend your investment horizon just slightly to the end of this year, the upside potential for this company is highly compelling.

GLTA